StreetInsider.com News Articles

Spyre (SYRE) PT Raised to $120 at Mizuho

Mon, 13 Jul 2026 06:46:05 -0400

(Updated - July 13, 2026 6:46 AM EDT)

Mizuho analyst Joseph Catanzaro raised the price target on Spyre (NASDAQ: SYRE) to $120.00 (from $84.00) while maintaining a Outperform rating.

The analyst commented: "Following a series of internal/external updates, as well as KOL feedback on dual pathway inhibition in IBD that strongly aligns with what SYRE has spoken to (note here), we're raising our PT to $120 from $84. We believe recent SKYLINE Part A data for SPY001 and SPY002 positions SPY120 for clinical remission rates that will have a high probability of showing superiority over an active monotherapy comparator. Such a profile

Spyre (SYRE) PT Raised to $120 at Mizuho

Mon, 13 Jul 2026 06:46:05 -0400

(Updated - July 13, 2026 6:46 AM EDT)

Mizuho analyst Joseph Catanzaro raised the price target on Spyre (NASDAQ: SYRE) to $120.00 (from $84.00) while maintaining a Outperform rating.

Form 4 Spyre Therapeutics, Inc. For: Jul 01 Filed by: Burrows Scott L

Thu, 02 Jul 2026 21:34:00 -0400

si-local-file:///var/storage/secattach/20260702/26730292.html

Form 4 Spyre Therapeutics, Inc. For: Jul 01 Filed by: Burrows Scott L

Thu, 02 Jul 2026 21:34:00 -0400

si-local-file:///var/storage/secattach/20260702/26730292.html

Form 4 Spyre Therapeutics, Inc. For: Jul 01 Filed by: Sloan Sheldon

Thu, 02 Jul 2026 21:33:00 -0400

si-local-file:///var/storage/secattach/20260702/26730291.html

Form 4 Spyre Therapeutics, Inc. For: Jul 01 Filed by: Sloan Sheldon

Thu, 02 Jul 2026 21:33:00 -0400

si-local-file:///var/storage/secattach/20260702/26730291.html

Form 4 Spyre Therapeutics, Inc. For: Jul 01 Filed by: Turtle Cameron

Thu, 02 Jul 2026 21:32:00 -0400

si-local-file:///var/storage/secattach/20260702/26730289.html

Form 4 Spyre Therapeutics, Inc. For: Jul 01 Filed by: Turtle Cameron

Thu, 02 Jul 2026 21:32:00 -0400

si-local-file:///var/storage/secattach/20260702/26730289.html

Spyre Therapeutics Announces Grants of Inducement Awards

Thu, 02 Jul 2026 16:05:00 -0400

WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 58,843 shares of common stock of Spyre and 2,134 restricted stock units (“RSUs”) to six non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018

Spyre Therapeutics Announces Grants of Inducement Awards

Thu, 02 Jul 2026 16:05:00 -0400

Spyre Therapeutics Announces Grants of Inducement Awards

Thu, 02 Jul 2026 16:05:00 -0400

Spyre Therapeutics Announces Grants of Inducement Awards

Thu, 02 Jul 2026 16:05:00 -0400

Form 144 Spyre Therapeutics, Inc. Filed by: Turtle Cameron

Wed, 01 Jul 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260701/26721902.html

Form 144 Spyre Therapeutics, Inc. Filed by: Turtle Cameron

Wed, 01 Jul 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260701/26721902.html

Form 4 Spyre Therapeutics, Inc. For: Jun 25 Filed by: Burrows Scott L

Fri, 26 Jun 2026 21:32:00 -0400

si-local-file:///var/storage/secattach/20260626/26700326.html

Form 4 Spyre Therapeutics, Inc. For: Jun 25 Filed by: Burrows Scott L

Fri, 26 Jun 2026 21:32:00 -0400

si-local-file:///var/storage/secattach/20260626/26700326.html

Spyre Therapeutics (SYRE) files mixed shelf

Fri, 26 Jun 2026 16:09:32 -0400

Spyre Therapeutics (NASDAQ: SYRE) has filed mixed shelf of:

COMMON STOCK
PREFERRED STOCK
DEBT SECURITIES
WARRANTS
UNITS

Spyre Therapeutics (SYRE) files mixed shelf

Fri, 26 Jun 2026 16:09:32 -0400

Spyre Therapeutics (NASDAQ: SYRE) has filed mixed shelf of:

COMMON STOCK
PREFERRED STOCK
DEBT SECURITIES
WARRANTS
UNITS

Form S-3ASR Spyre Therapeutics, Inc.

Fri, 26 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260626/26698701.html

Form S-3ASR Spyre Therapeutics, Inc.

Fri, 26 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260626/26698701.html

Form 144 Spyre Therapeutics, Inc. Filed by: Burrows Scott L

Thu, 25 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260625/26692240.html

Form 144 Spyre Therapeutics, Inc. Filed by: Burrows Scott L

Thu, 25 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260625/26692240.html

Form 144 Spyre Therapeutics, Inc. Filed by: Fairmount Funds Management LLC

Tue, 23 Jun 2026 21:58:00 -0400

si-local-file:///var/storage/secattach/20260623/26681144.html

Form 144 Spyre Therapeutics, Inc. Filed by: Fairmount Funds Management LLC

Tue, 23 Jun 2026 21:58:00 -0400

si-local-file:///var/storage/secattach/20260623/26681144.html

Form 4 Spyre Therapeutics, Inc. For: Jun 23 Filed by: Fairmount Healthcare Fund II L.P.

Tue, 23 Jun 2026 21:56:00 -0400

si-local-file:///var/storage/secattach/20260623/26681139.html